[ad_1]
Washington – The United States, as the outbreak of the new Corona virus that infected 12 million people in its soil accelerates, has allowed the use of an innovative treatment developed by “Regeneron” and was used specifically to treat US President Donald Trump .
The United States is the country most affected by the epidemic in the world, with 255,800 deaths. The disease is spreading uncontrollably and the number of daily infections is increasing dramatically, with the total number of infections having surpassed 12 million, according to Johns Hopkins University.
Faced with this crisis, the US Food and Drug Administration (FDA) granted urgent approval on Saturday to use a treatment that is a combination of antibodies developed by the biotechnology company Regeneron. This treatment is known to have been used to treat Trump, which he bragged about after he recovered from the disease in October.
According to the US Food and Drug Administration, the Regeneron treatment, called Regen-Cove-2, which is a combination of two antibodies made in a laboratory, reduces Covid-19 infections that require hospitalization or emergency rooms. in people with secondary diseases or “Comorbidities”.
“Allowing these monoclonal antibody therapies can allow patients to avoid hospitalization and reduce the burden on our health care system,” said an FDA official, Stephen Hahn.
Regeneron CEO Leonard Schleifer said this decision constitutes “an important step in the fight against Covid-19, as high-risk patients in the United States will be able to obtain promising treatment early in the course of the disease. infection”.
It is considered most effective in the first stage of the virus infection, when the antibodies still have a chance to control the disease and not in the second stage of the infection, when the virus itself does not become dangerous but rather an overreaction of the immune system that attacks the lungs and other organs.
Regeneron is the second synthetic antibody treatment to receive an “urgent use license” from the US Food and Drug Administration. Approval to use a similar treatment developed by the US company Eli Lilly was granted on November 9.
Regeneron has signed several contracts with the US administration, including a contract worth up to $ 450 million, to manufacture a large number of doses in the United States. In late October, the government announced the purchase of 300,000 doses of the “Nighty” treatment for $ 375 million, or $ 1,250 per dose.
The approval granted to Regeneron adds to the good news in terms of vaccines, with an efficacy rate of 95% for the two vaccines developed by Pfizer / Bionic Alliance and Moderna.
